Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Navigating the advanced NSCLC patient pathway: New markers and targets - An interactive case study

Presented by Johan Vansteenkiste

Respiratory Oncology Unit, Dept. Pulmonology, Univ. Hospital KU Leuven, Leuven Lung Cancer Group.

This interactive case study is based on a presentation given by Johan Vansteenkiste, at a Springer Healthcare independent symposium at the ELCC 2016.

The purpose of this interactive case study of is for participants to test their knowledge and clinical practices in the management of patients with NSCLC, and gain knowledge of emerging first-line and relapse treatment pathways.

Case study

Click the image below to access the case study:


Please allow approximately 20–30 minutes to complete this module. Your progress will be tracked allowing you to return to your most recently viewed screen.

Learning objectives

On completing this assessment, you should to be able to:

  • Describe the unique challenges in treating patients with squamous NSCLC
  • Explain the current treatment strategies for patients with squamous NSCLC, according to ESMO guidelines
  • Compare and contrast first-line treatment strategies for patients with squamous NSCLC
  • Discuss new and emerging relapse treatment pathways for patients with squamous NSCLC

Presenter's biography

Target audience

This case study is intended for medical and radiation oncologists, thoracic surgeons, pulmonologists, respiratory physicians and any other clinicians involved in the diagnosis, treatment and follow-up of patients with non–small cell lung cancer (NSCLC).

Educational grant

Support for this educational activity is provided by Eli Lilly and Company.

Produced by Springer Healthcare IME.

Contact us

Email: IME@springer.com
Telephone +44 (0) 203 192 2023
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK